For Immediate Release: December 1, 2015

Mary Kuramoto
513-579-9911 x2523

Medpace Continues to Expand Global Infectious Disease and Vaccine Drug Development Capabilities Prasad Velisetty M.D. Joins Medpace as Senior Medical Director, Medical Affairs

CINCINNATI, OH — (December 1, 2015) – Prasad Velisetty, M.D. has joined Medpace as Senior Medical Director for Infectious Diseases and Vaccines Medical Affairs. Dr. Velisetty brings over 11 years of Phase I-IV medical and scientific leadership in clinical research including his recent expertise as Regional Chief medical officer of Europe Middle East and Africa at a major CRO. His therapeutic experience spans infectious disease and vaccines, allergy, respiratory, gastrointestinal, women’s health, dermatology, pediatrics, immunology and critical care.

Within the infectious disease and vaccine therapeutic area, Dr. Velisetty has provided medical leadership on numerous clinical research studies and programs including Influenza, RSV, HIV, Hepatitis B and C, health care associated pneumonia, community acquired pneumonia, skin and soft tissue infections, reproductive tract infections, invasive fungal disease, TB as well as other tropical diseases trials. With broad industry experience including strategic drug development consulting, global feasibilities, early clinical development, and life cycle safety. Dr. Velisetty brings a diverse perspective to Sponsors developing infectious disease and vaccine therapies. In addition, Dr. Velisetty still maintains his clinical practice, providing care to HIV/Genitourinary medicine patients in UKs National Health Service as well as academic appointments at Kings College, London.

Dr. Velisetty earned his medical degree at the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), in Pondicherry, India and completed his internship and residency in Community medicine at Post Graduate Institute of Medical Education and Research (PGIMER), University in Chandigarh, India. He is an active industry participant with numerous published manuscripts, speaking engagements, industry memberships, awards and honors.


Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace is unique in its physician-driven approach to clinical research which gives Sponsors the advantage of early and ongoing insight and guidance from therapeutic experts throughout trial design and execution. Medpace has strong experience supporting development programs across a number of therapeutic and specialty areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, gastrointestinal diseases, regenerative medicine, pediatrics, and rare disease/orphan indications. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2300 employees and has clinical trial experience in over 45 countries and six regions – the US, Europe, Central and Eastern Europe, India, Asia Pacific, and Africa. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.

For more information, please visit